Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CPX-351 induction for newly diagnosed low/intermediate-risk AML without FLT3 mutation
MOH_2022-01-10_010518Phase 2Recruiting
- Sponsor
- ד"ר חזי גנזל
- Start
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cytarabine in acute myeloid leukemia (AML), sponsored by ד"ר חזי גנזל. Primary endpoints: Treatment response rate and Safety. Started Aug 2021; status: recruiting.
02
Drugs
cytarabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on MOH_2022-01-10_010518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-01-10_010518.